Skip to main content
SpringerLink
Log in

Onkologika

  • Chapter
Arzneiverordnungs-Report 2017

Zusammenfassung

In der medikamentösen Tumortherapie werden heute zahlreiche Wirkstoffklassen mit unterschiedlichen Wirkmechanismen eingesetzt. Zytostatika waren die ersten Arzneimittel, die vor mehr als 70 Jahren die Ära der antineoplastischen Chemotherapie einleiteten (DeVita und Rosenberg 2012). Auch heute sind sie weiterhin die am häufigsten angew endeten Arzneimittel in der Krebstherapie. Durch ihren Einsatz als Monotherapie, vor allem aber in empirisch entwickelten Polychemotherapien, wurden große Fortschritte in der Behandlung von hämatologischen Neoplasien erzielt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 64.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Adams JL, Smothers J, Srinivasan R, Hoos A (2015): Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov 14: 603–622

    Google Scholar 

  • Al-Lazikani B, Banerji U, Workman P (2012): Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 30: 679–692

    Google Scholar 

  • André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A (2009): Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27: 3109–3116

    Google Scholar 

  • Apperley JF (2015): Chronic myeloid leukaemia. Lancet 385: 1447–1459.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2017): Leitfaden zu Biosimilars, 1. Auflage. https://www.akdae.de/Arzneimitteltherapie/LF/PDF/Biosimilars.pdf

  • Attard G, Parker C, Eeles RA, Schröder F, Tomlins SA, Tannock I, Drake CG, de Bono JS (2016): Prostate cancer. Lancet 387: 70–82

    Google Scholar 

  • Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013): European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122: 872–884

    Google Scholar 

  • Barbui T, Finazzi MC, Finazzi G (2012): Front-line therapy in polycythemia vera and essential thrombocythemia. Blood Rev 26: 205–211

    Google Scholar 

  • Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators (2014): Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371: 424–433

    Google Scholar 

  • Beyer J, Albers P, Altena R, Aparicio J et al (2013): Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 24: 878–888

    Google Scholar 

  • Bundesministerium für Gesundheit (2013): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Crizotinib vom 2. Mai 2013 veröffentlicht am Montag, 3. Juni 2013 BAnz AT 03.06.2013 B2

    Google Scholar 

  • Bundesministerium für Gesundheit (2014): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V), Ruxolitinib vom 6. November 2014, veröffentlicht Montag, 15. Dezember 2014, BAnz AT 15.12.2014 B4

    Google Scholar 

  • Bundesministerium für Gesundheit (2015): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V) Nintedanib vom 18. Juni 2015 veröffentlicht am Donnerstag, 23. Juli 2015 BAnz AT 23.07.2015 B2

    Google Scholar 

  • Bundesministerium für Gesundheit (2016): Bekanntmachung eines Beschlusses des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII – Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach § 35a des Fünften Buches Sozialgesetzbuch (SGB V), Crizotinib (neues Anwendungsgebiet) Vom 16. Juni 2016 veröffentlicht am Dienstag, 20. September 2016 BAnz AT 20.09.2016 B2

    Google Scholar 

  • Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A, de Vos S, Gill D, Bloor A, Dearden C, Moreno C, Jones JJ, Chu AD, Fardis M, McGreivy J, Clow F, James DF, Hillmen P; RESONATE Investigators (2014a): Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 371: 213–223

    Google Scholar 

  • Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM (2014b): Entering the era of targeted therapy for chronic lymphocytic leukemia: Impact on the practicing clinician. J Clin Oncol 32: 3039–3047

    Google Scholar 

  • Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C; Herceptin Adjuvant (HERA) Trial Study Team (2017): 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389:1195–1205

    Google Scholar 

  • Ciardiello F, Tortora G (2008): EGFR antagonists in cancer treatment. N Engl J Med 358: 1160–1174

    Google Scholar 

  • Cervantes F (2014): How I treat myelofibrosis. Blood 124: 2635–2642

    Google Scholar 

  • Cheson BD, Leonard JP (2008): Monoclonal antibody therapy for B-cell non-Hodgkin’s lymphoma. N Engl J Med 359: 613–626

    Google Scholar 

  • Cheson BD, Rummel MJ (2009): Bendamustine: rebirth of an old drug. J Clin Oncol 27: 1492–1501

    Google Scholar 

  • Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X (2015): New immunotherapies targeting the PD-1 pathway. Trends Pharmacol Sci 36: 587–595

    Google Scholar 

  • Ciardiello F, Tortora G (2008): EGFR antagonists in cancer treatment. N Engl J Med 358: 1160–1174

    Google Scholar 

  • Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002): CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235–242

    Google Scholar 

  • Collins FS, Varmus H (2015): A new initiative on precision medicine. N Engl J Med 372: 793–795

    Google Scholar 

  • Cortes J, O’Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus E7389) investigators (2011): Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377: 914–923

    Google Scholar 

  • Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al. (2004): A randomised comparison of cetuximab monotherapy and cetuximab plus Irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345

    Google Scholar 

  • Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF; ATAC/LATTE investigators (2010): Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11: 1135–1141

    Google Scholar 

  • De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators (2010): Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376: 1147–1154

    Google Scholar 

  • Deutsche Krebsgesellschaft e.V., Deutschen Krebshilfe, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (2015): S3-Leitlinie Diagnostik, Therapie und Nachsorge des Nierenzellkarzinoms. Langversion 1.0 – September 2015 AWMF-Registernummer: 043/017-OL. Internet: http://leitlinienprogramm-onkologie.de/Nierenzellkarzinom.85.0.html

  • Deutsche Krebsgesellschaft e.V., Deutschen Krebshilfe, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (Hrsg) (2016): Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. Langversion 4.0 – Dezember 2016, AWMF-Register-Nummer 043/022OL. Federführende Fachgesellschaft Deutsche Gesellschaft für Urologie e. V. (DGU). Internet: http://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/

  • Deutsche Krebsgesellschaft e.V., Deutschen Krebshilfe, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (Hrsg) (2017): Konsultationsfassung S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms Langversion 0.4.0– Juni 2017, AWMF-Registernummer: 032-045OL Federführende Fachgesellschaften Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG), Deutsche Krebsgesellschaft (DKG): Internet: http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/

  • DeVita VT, Rosenberg SA (2012): Two hundred years of cancer research. N Engl J Med 366: 2207–2214

    Google Scholar 

  • Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M (2010): Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28: 4594–4600

    Google Scholar 

  • Dobbelstein M, Moll U (2014): Targeting tumour-supportive cellular machineries in anticancer drug development. Nat Rev Drug Discov 13: 179–196

    Google Scholar 

  • Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J (2010): Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697–4705

    Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005): Effects of chemotherapy and hormonal therapy for early breast can cer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687–1717

    Google Scholar 

  • Eichhorst B, Hallek M (2016): Neue Therapiekonzepte bei der chronisch-lymphatischen Leukämie. Onkologe 22: 283–294

    Google Scholar 

  • Ellis MJ, Llombart-Cussac A, Feltl D, Dewar JA, Jasiówka M, Hewson N, Rukazenkov Y, Robertson JF (2015): Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: Overall survival analysis from the phase II FIRST study. J Clin Oncol 33: 3781–3787

    Google Scholar 

  • Ernst E, Schmidt K, Steuer-Vogt MK (2003): Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer 107: 262–267

    Google Scholar 

  • European Medicines Agency (2016): CHMP confirms recommendations for use of Zydelig. Patients should be monitored for infection and given antibiotics during and after treatment. Internet: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2016/07/news_detail_002573.jsp&mid=WC0b01ac058001d126

  • Evans JB, Syed BA (2014): From the analyst’s couch: Nextgeneration antibodies. Nat Rev Drug Discov 13: 413–414

    Google Scholar 

  • Falchi L, Bose P, Newberry KJ, Verstovsek S (2017): Approach to patients with essential thrombocythaemia and very high platelet counts: what is the evidence for treatment? Br J Haematol 176: 352–364

    Google Scholar 

  • Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group (2009): Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10: 223–232

    Google Scholar 

  • Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroğlu M, Ye D, Feyerabend S, Protheroe A, De Porre P, Kheoh T, Park YC, Todd MB, Chi KN; LATITUDE Investigators (2017): Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 377:352–360

    Google Scholar 

  • Foà R (2014): Changes in the treatment landscape for chronic lymphoid leukemia. N Engl J Med 371: 273–274

    Google Scholar 

  • Food and Drug Administration (2011): FDA Commissioner removes breast cancer indication from avastin label. Internet: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm279485.htm

  • Fruman DA, Rommel C (2014): PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13: 140–156

    Google Scholar 

  • Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM, Dansey RD, Hallek M, O’Brien SM (2014): Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370: 997–1007

    Google Scholar 

  • Gerecke C, Fuhrmann S, Strifler S, Schmidt-Hieber M, Einsele H, Knop S (2016): Diagnostik und Therapie des Multiplen Myeloms. Dtsch Ärztebl 113: 470–476

    Google Scholar 

  • Gharwan H, Groninger H (2016): Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol 13: 209–227

    Google Scholar 

  • Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR (2016): Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375: 209–219

    Google Scholar 

  • Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA (2016): First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev. 2016 May 25; (5): CD010383

    Google Scholar 

  • Gregory RK, Smith IE (2000): Vinorelbine - a clinical review. Br J Cancer 82: 1907–1913

    Google Scholar 

  • Hanahan D (2014): Rethinking the war on cancer. Lancet 383: 558–563

    Google Scholar 

  • Harris M (2004): Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 5: 292–302

    Google Scholar 

  • Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study (2005): Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353: 33–45

    Google Scholar 

  • Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012): JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366: 787–798

    Google Scholar 

  • Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB (2012): Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380: 358–365Hassel JC, Heinzerling L, Aberle J, Bähr O, Eigentler TK, Grimm MO, Grünwald V, Leipe J, Reinmuth N, Tietze JK, Trojan J, Zimmer L, Gutzmer R (2017): Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. Cancer Treat Rev. 57:36–49

    Google Scholar 

  • Ho GY, Woodward N, Coward JI (2016): Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Crit Rev Oncol Hematol 102: 37–46

    Google Scholar 

  • Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O’Brien SG, Druker BJ; IRIS Investigators (2017). Longterm outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 376:917–927

    Google Scholar 

  • Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C (2002): Fulvestrant (ICI 182,780) is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing progressing after prior endocrine treatment. J Clin Oncol 20: 3396–3403

    Google Scholar 

  • Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK (2004): Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 22: 1605–1613

    Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004): Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342

    Google Scholar 

  • James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O’Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR; STAMPEDE Investigators (2017): Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 377:338–351

    Google Scholar 

  • Jayson GC, Kohn EC, Kitchener HC, Ledermann JA (2014): Ovarian cancer. Lancet 384: 1376–1388

    Google Scholar 

  • Joppi R, Gerardi C, Bertele V, Garattini S (2016): Letting post-marketing bridge the evidence gap: the case of orphan drugs. BMJ 353:i2978. doi: 10.1136/bmj.i2978

  • Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, Guo CC, Lotan Y, Kassouf W (2016): Bladder cancer. Lancet 388: 2796–2810

    Google Scholar 

  • Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS (2017): Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376:836–847

    Google Scholar 

  • Khasraw M, Bell R, Dang C (2012): Epirubicin: is it like doxorubicin in breast cancer? A clinical review. Breast 21: 142–149

    Google Scholar 

  • Kamisawa T, Wood LD, Itoi T, Takaori K (2016): Pancreatic cancer. Lancet 388: 73–85

    Google Scholar 

  • Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S (2015): Immuntherapie von Tumoren. Aktivierte T-Zellen als neues Behandlungsprinzip. Dtsch Arztebl 112: 809–815

    Google Scholar 

  • Kundranda MN, Niu J (2015): Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des Devel Ther 9: 3767–3777

    Google Scholar 

  • Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Lafrate AJ (2010): Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693–1703

    Google Scholar 

  • Lao J, Madani J, Puértolas T, Alvarez M, Hernández A, Pazo-Cid R, Artal A, Antón Torres A (2013): Liposomal doxorubicin in the treatment of breast cancer patients: a review. Drug Deliv 2013: 456409

    Google Scholar 

  • Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Jurczyszyn A, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim CS, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O’Gorman P, Terpos E, McCarthy P, Dimopoulos M, Moreau P, Orlowski RZ, Miguel JS, Anderson KC, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson PG (2016): Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. Leukemia 30:1005–17

    Google Scholar 

  • Lecavalier-Barsoum M, Quon H, Abdulkarim B (2014): Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database Syst Rev. 2014 May 15; 5: CD007104

    Google Scholar 

  • Lorente D, Fizazi K, Sweeney C, de Bono JS (2015): Optimal treatment sequence for metastatic castration-resistant prostate cancer. Eur Urol Focus 2: 488–498

    Google Scholar 

  • Macedo LT, da Costa Lima AB, Sasse AD (2012): Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer 12:89. doi: 10.1186/1471-2407-12-89

  • Mailankody S, Prasad V (2015): Five years of cancer drug approvals: Innovation, efficacy, and costs. JAMA Oncol 1: 539–540

    Google Scholar 

  • Malik P, Cashen AF (2014): Decitabine in the treatment of acute myeloid leukemia in elderly patients. Cancer Manag Res 6:53–61

    Google Scholar 

  • Martí-Carvajal AJ, Anand V, Solà I (2015): Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis. Cochrane Database Syst Rev. 2015 Apr 10; 4: CD010298

    Google Scholar 

  • Meyerhardt JA, Mayer RJ (2005): Systemic therapy for colorectal cancer. N Engl J Med 352: 476–487

    Google Scholar 

  • Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M (2009): Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947–957

    Google Scholar 

  • Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK (2013): Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369: 722–731

    Google Scholar 

  • Nagasawa DT, Chow F, Yew A, Kim W, Cremer N, Yang I (2012): Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg Clin N Am 23: 307–322

    Google Scholar 

  • National Institute for Health and Clinical Excellence (NICE) (2011): Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer. Internet: guidance.nice.org.uk/TA214/Guidance/pdf/English

    Google Scholar 

  • National Institute of Health and Clinical Excellence (2014): Prostate cancer. Diagnosis and treatment. Issued: January 2014, NICE clinical guideline 175. Internet: http://www.nice.org.uk/guidance/cg175/resources/nice-diagnosing-and-treating-prostate-cancer

  • Navarra P, Preziosi P (1999): Hydroxyurea: new insights on an old drug. Crit Rev Oncol Hematol 29: 249–255

    Google Scholar 

  • O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ; IRIS Investigators (2003): Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994–1004

    Google Scholar 

  • Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A (2002): A double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant with anastrozole in post-menopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 20: 3386–3395

    Google Scholar 

  • Palumbo A, Mina R (2013): Management of older adults with multiple myeloma. Blood Rev 27:133–142

    Google Scholar 

  • Pardoll DM (2012): The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252–264

    Google Scholar 

  • Park K, Tan EH, O’Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L (2016): Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 2016 Apr 12. pii: S1470-2045(16)30033-X. doi: 10.1016/S1470-2045(16)30033-X. [Epub ahead of print]

  • Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr, Martino S, Rastogi P, Gralow J, Swain SM, Winer EP, Colon-Otero G, Davidson NE, Mamounas E, Zujewski JA, Wolmark N (2014): Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32: 3744–3752

    Google Scholar 

  • Pizzolato JF, Saltz LB (2003): The camptothecins. Lancet 361: 2235–2242

    Google Scholar 

  • Pox C, Schmiegel W, Reinacher-Schick A (2012): Kolorektales Karzinom – Was gibt’s Neues? Dtsch med Wochenschr 137: 2577–2580

    Google Scholar 

  • Rafiyan MR, Jäger E (2013): Medikamentöse Behandlung des metastasierten Nierenzellkarzinoms. Dtsch Med Wochenschr 138: 1567–1570

    Google Scholar 

  • Ranpura V, Hapani S, Wu S (2011): Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 305: 487–494

    Google Scholar 

  • Rajkumar SV, Kyle RA (2016) Progress in Myeloma – A monoclonal breakthrough. N Engl J Med 375: 1390–1392

    Google Scholar 

  • Rajkumar SV, Harosseau JC (2016): Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. Blood 128: 2757–2764

    Google Scholar 

  • Raza S, Safyan, Rosenbaum E, Bowman AS, Lentzsch S (2017): Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist. Ther Adv Hematol 8: 55–70

    Google Scholar 

  • Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M, von Pawel J, Gottfried M, Bondarenko I, Liao M, Gann CN, Barrueco J, Gaschler-Markefski B, Novello S; LUME-Lung 1 Study Group (2014): Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15: 143–155

    Google Scholar 

  • Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Her A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA (2015a): Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372: 320–330

    Google Scholar 

  • Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, Blank CU, Hamid O, Mateus C, Shapira-Frommer R, Kosh M, Zhou H, Ibrahim N, Ebbinghaus S, Ribas A; KEYNOTE-006 investigators (2015b): Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372: 2521–2532

    Google Scholar 

  • Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D (2015c): Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372: 30–39

    Google Scholar 

  • Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, Lindemann J, Ellis MJ (2009): Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 27: 4530–4535

    Google Scholar 

  • Rosario DJ, Davey P, Green J, Greene D, Turner B, Payne H, Kirby M (2016): The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK. World J Urol. 2016 Apr 20. [Epub ahead of print]

    Google Scholar 

  • Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators (2013): Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368: 138–148

    Google Scholar 

  • Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators (2015): Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16: 152–160

    Google Scholar 

  • San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M (2013): Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, openlabel, phase 3 trial. Lancet Oncol 14: 1055–1066

    Google Scholar 

  • San Miguel J (2015): Introduction to a series of reviews on multiple myeloma. Blood 125: 3039-40

    Google Scholar 

  • Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J (2008): Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013–2019

    Google Scholar 

  • Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators (2012): Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367: 1187–1197

    Google Scholar 

  • Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J (2014): Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction. J Pediatr Hematol Oncol 36: 503–517

    Google Scholar 

  • Scott AM, Wolchok JD, Old LJ (2012): Antibody therapy of cancer. Nat Rev Cancer 12: 278–287

    Google Scholar 

  • Shankland KR, Armitage JO, Hancock BW (2012): Non-Hodgkin lymphoma. Lancet 380: 848–857

    Google Scholar 

  • Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O’Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA (2013): Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368: 2385–2394

    Google Scholar 

  • Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer Institute of Canada Clinical Trials Group (2005): Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132

    Google Scholar 

  • Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001): Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792

    Google Scholar 

  • Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF (2012): Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30: 2055–2062

    Google Scholar 

  • Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O’Reilly EM, Uronis HE, Ramanathan RK, Crane CH, Engebretson A, Ruggiero JT, Copur MS, Lau M, Urba S, Laheru D (2016): Metastatic pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 34: 2784–2796

    Google Scholar 

  • Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S, Reisman A, Wilner KD, Tursi J, Blackhall F; PROFILE 1014 Investigators (2014): First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371: 2167–2177

    Google Scholar 

  • Sonpavde G, Wang CG, Galsky MD, Oh WK, Armstrong AJ (2014): Cytotoxic chemotherapy in the contemporary management of metastatic prostate cancer. BJU Int 116: 17–29

    Google Scholar 

  • Stilgenbauer S, Hallek M (2013): Chronische lymphatische Leukämie. Therapie und genetisches Risikoprofil. Internist 54:164–170

    Google Scholar 

  • Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group (2005): Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987–996

    Google Scholar 

  • Swain SM, Kim SB, Cortés J, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Knott A, Clark E, Ross G, Benyunes MC, Baselga J (2013): Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14: 461–471

    Google Scholar 

  • Thompson PA, Kantarjian HM, Cortes JE (2015): Diagnosis and treatment of chronic myeloid leukemia in 2015. Mayo Clin Proc 90: 1440–1454

    Google Scholar 

  • Tomasini P, Barlesi F, Mascaux C, Greillier L (2016): Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes. Ther Adv Med Oncol 8: 198–208

    Google Scholar 

  • Trinh VA, Davis JE, Anderson JE, Kim KB (2014): Dabrafenib therapy for advanced melanoma. Ann Pharmacother 48: 519–529

    Google Scholar 

  • Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F (2011): Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011–2019

    Google Scholar 

  • Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007): Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25: 1658–1664

    Google Scholar 

  • Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C (2012): Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30: 3499–3506

    Google Scholar 

  • van Dalen EC, van der Pal HJ, Kremer LC (2016): Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2016 Mar 3;3:CD005008. doi: 10.1002/14651858.CD005008.pub4

  • van de Donk NWCJ, Moreau P, Plesner T, Palumbo A, Gay F, Laubach JP, Malavasi F, Avet-Loiseau H, Mareos M-V, Sonneveld P, Lokhorst HM, Richardson PG (2016): Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood 127: 681–695

    Google Scholar 

  • Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S (2015): Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372: 426–435

    Google Scholar 

  • Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group (2012): Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367: 1783–1791

    Google Scholar 

  • Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012): A doubleblind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366: 799–807

    Google Scholar 

  • Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013): Cancer genome landscapes. Science 339: 1546–1558

    Google Scholar 

  • Weeraratna AT (2012): RAF around the edges – the paradox of BRAF inhibitors. N Engl J Med 366: 271–273

    Google Scholar 

  • Wagner AD, Thomssen C, Haerting J, Unverzagt S (2012): Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database Syst Rev. 2012 Jul 11; 7: CD008941

    Google Scholar 

  • Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA (2013): Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369: 507–516

    Google Scholar 

  • Wang Y, Yang F, Shen Y, Zhang W, Wang J, Chang VT, Andersson BS, Qazilbash MH, Champlin RE, Berenson JR, Guan X, Wang ML (2016): Maintenance therapy with immunomodulatory drugs in multiple myeloma: A meta-analysis and systematic review. J Natl Cancer Inst 108: 1–10

    Google Scholar 

  • Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M; NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society (2012): Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13: 707–715

    Google Scholar 

  • Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O’Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV (2015): Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol 16: 141–151

    Google Scholar 

  • Young RM, Staudt LM (2013): Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 12: 229–243

    Google Scholar 

  • Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C (2011): Erlotinib versus chemotherapy as firstline treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735–742

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Arzneimittelkommission der deutschen Ärzteschaft, Herbert-Lewin-Platz 1, 10623, Berlin, Deutschland

    Wolf-Dieter Ludwig

  2. Pharmakologisches Institut, Universität Heidelberg Im Neuenheimer Feld 366, 69120, Heidelberg, Deutschland

    Ulrich Schwabe

Authors
  1. Wolf-Dieter Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolf-Dieter Ludwig .

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Deutschland

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln, Deutschland

    Dieter Paffrath

  3. Arzneimittelkommission der deutschen Ärzteschaft, Herbert-Lewin-Platz 1, 10623, Berlin, Deutschland

    Wolf-Dieter Ludwig

  4. Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178, Berlin, Deutschland

    Jürgen Klauber

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer-Verlag GmbH Germany

About this chapter

Cite this chapter

Ludwig, WD., Schwabe, U. (2017). Onkologika. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2017. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-54630-7_37

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-54630-7_37

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-54629-1

  • Online ISBN: 978-3-662-54630-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation